Apyx Medical Past Earnings Performance
Past criteria checks 0/6
Apyx Medical's earnings have been declining at an average annual rate of -5.4%, while the Medical Equipment industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 20.1% per year.
Key information
-5.4%
Earnings growth rate
-4.8%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 20.1% |
| Return on equity | -70.0% |
| Net Margin | -35.7% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18
Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
Feb 16Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Sep 14Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?
Jun 07Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically
Mar 21Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation
Dec 14We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate
Aug 30Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M
Aug 11Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin
Jul 18Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth
May 26Are Investors Undervaluing Apyx Medical Corporation (NASDAQ:APYX) By 42%?
Mar 15We Think Apyx Medical (NASDAQ:APYX) Can Easily Afford To Drive Business Growth
Jan 08We Think Apyx Medical (NASDAQ:APYX) Can Easily Afford To Drive Business Growth
Sep 28Revenue & Expenses BreakdownBeta
How Apyx Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 52 | -19 | 49 | 5 |
| 30 Sep 23 | 50 | -15 | 48 | 5 |
| 30 Jun 23 | 47 | -16 | 47 | 5 |
| 31 Mar 23 | 44 | -21 | 47 | 5 |
| 31 Dec 22 | 45 | -23 | 48 | 5 |
| 30 Sep 22 | 49 | -19 | 48 | 4 |
| 30 Jun 22 | 51 | -18 | 48 | 4 |
| 31 Mar 22 | 52 | -16 | 47 | 4 |
| 31 Dec 21 | 49 | -15 | 44 | 4 |
| 30 Sep 21 | 43 | -15 | 40 | 4 |
| 30 Jun 21 | 38 | -14 | 37 | 4 |
| 31 Mar 21 | 31 | -15 | 34 | 4 |
| 31 Dec 20 | 28 | -12 | 34 | 4 |
| 30 Sep 20 | 25 | -16 | 34 | 4 |
| 30 Jun 20 | 25 | -16 | 35 | 4 |
| 31 Mar 20 | 28 | -16 | 36 | 4 |
| 31 Dec 19 | 28 | -20 | 35 | 4 |
| 30 Sep 19 | 26 | -18 | 34 | 3 |
| 30 Jun 19 | 22 | -15 | 29 | 3 |
| 31 Mar 19 | 19 | -14 | 26 | 3 |
| 31 Dec 18 | 17 | -11 | 22 | 3 |
| 30 Sep 18 | 14 | -10 | 18 | 2 |
| 30 Jun 18 | 13 | -12 | 17 | 2 |
| 31 Mar 18 | 5 | -15 | 17 | 2 |
| 31 Dec 17 | 10 | -14 | 17 | 2 |
| 30 Sep 17 | -12 | -19 | 15 | 1 |
| 30 Jun 17 | -4 | -17 | 15 | 1 |
| 31 Mar 17 | 37 | -4 | 20 | 3 |
| 31 Dec 16 | 9 | -12 | 15 | 1 |
| 30 Sep 16 | 35 | -5 | 18 | 3 |
| 30 Jun 16 | 33 | -5 | 18 | 2 |
| 31 Mar 16 | 31 | -6 | 18 | 2 |
| 31 Dec 15 | 30 | 8 | 17 | 2 |
| 30 Sep 15 | 29 | 4 | 17 | 2 |
| 30 Jun 15 | 28 | 3 | 16 | 2 |
| 31 Mar 15 | 27 | 4 | 16 | 2 |
| 31 Dec 14 | 28 | -18 | 13 | 1 |
| 30 Sep 14 | 26 | -18 | 14 | 1 |
| 30 Jun 14 | 25 | -15 | 11 | 1 |
| 31 Mar 14 | 24 | -16 | 11 | 1 |
| 31 Dec 13 | 24 | -7 | 12 | 1 |
| 30 Sep 13 | 24 | -2 | 10 | 1 |
| 30 Jun 13 | 25 | -1 | 11 | 1 |
Quality Earnings: APYX is currently unprofitable.
Growing Profit Margin: APYX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APYX is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.
Accelerating Growth: Unable to compare APYX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APYX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.9%).
Return on Equity
High ROE: APYX has a negative Return on Equity (-70.02%), as it is currently unprofitable.